Competition in the drug market: Safe again?
Two pharmaceutical companies that have waited patiently to complete their $3.4 billion deal may proceed under strict conditions, though one Commissioner has questioned the ultimate effectiveness of the consent order....To view the full article, register now.
Already a subscriber? Click here to view full article